Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: Pooled analysis of two trials

Orphanet Journal of Rare Diseases

Volumn 11, Issue 1, 2016, Pages

  Chang, Anne Lynn S ^a   Arron, Sarah T ^b   Migden, Michael R ^c   Solomon, James A ^d,e,f   Yoo, Simon ^g   Day, Bann Mo ^h   McKenna, Edward F ^h   Sekulic, Aleksandar ⁱ  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Ameriderm Research   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA   (United States)

^f UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h GENENTECH INC   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

Basal cell carcinoma; Basal cell carcinoma nevus syndrome; Vismodegib

Indexed keywords

VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN;

ADULT; ADVANCED CANCER; ALOPECIA; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METASTASIS; MUSCLE SPASM; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; AGED; CARCINOMA, BASAL CELL; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; SKIN NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; PYRIDINES; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84984918426     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-016-0506-z     Document Type: Article

References (10)

1. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-54.
2. Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer. 2011;2011:650258.
3. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;25(3):218-23.
4. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32.
5. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-9.
6. Tang JY, Kay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-8.
7. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60-9.
8. Sekulic A, Weiss GJ, Solomon JA, Rudin CM, Guillot B, Williams S, et al. Amenorrhea or irregular menses in patients treated with vismodegib. Presented at: 2014 Winter Clinical Dermatology Conference Hawaii; Kohala Coast, Hawaii. 2014
9. Spicer LJ, Sudo S, Aad PY, Wang LS, Chun SY, Ben-Shlomo I, et al. The hedgehog-patched signaling pathway and function in the mammalian ovary: a novel role for hedgehog proteins in stimulating proliferation and steroidogenesis of theca cells. Reproduction. 2009;138(2):329-39.
10. Strasswimmer J, Latimer B, Ory S. Amenorrhea secondary to a vismodegib-induced blockade of follicle-stimulating hormone-receptor activation. Fertil Steril. 2014;102(2):555-7.